NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand

Wajih Bukhari; Elham Khalilidehkordi; Deborah F. Mason; Michael H. Barnett; Bruce V. Taylor; Marzena Fabis-Pedrini; Allan G. Kermode; Sankar Subramanian; Patrick Waters; Simon A. Broadley; The Australian and New Zealand NMO Collaboration

doi:10.1007/s00415-021-10665-9

NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand

Wajih Bukhari, Elham Khalilidehkordi, Deborah F. Mason, Michael H. Barnett, Bruce V. Taylor, Marzena Fabis-Pedrini, Allan G. Kermode, Sankar Subramanian, Patrick Waters, Simon A. Broadley, The Australian and New Zealand NMO Collaboration

Research output: Contribution to journal › Article › peer-review

6 Citations (Scopus)

Abstract

Background: We studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences. Methods: Cases of possible NMOSD and MS were collected from Australia and New Zealand. Clinical details, MR imaging, and serologic results were used to apply 2015 IPND diagnostic criteria for NMOSD and 2010 McDonald criteria for MS. Frequencies of self-determined ethnic ancestry were calculated for confirmed NMOSD, suspected NMOSD, and MS. Prevalence rates for NMOSD and MS according to ancestry were compared. Results: There were 75 cases with NMOSD, 89 with suspected NMSOD, and 101 with MS. NMOSD cases were more likely to have Asian, Indigenous, or Other ancestry compared to suspected NMOSD or MS. There were no differences in the clinical phenotype of NMOSD seen in Indigenous compared to European ancestry populations. Per 100,000, the prevalence estimate for NMOSD in people with Māori ancestry was 1.50 (95% CI 0.52–2.49) which was similar to those with Asian ancestry 1.57 (95% CI 1.15–1.98). NMOSD prevalence in Australian Aboriginal and Torres Strait Islander populations was 0.38 (95% CI 0.00–0.80) per 100,000. Conclusion: The prevalence of NMOSD in the Māori population is similar to South East Asian countries, reflecting their historical origins. The prevalence of MS in this group is intermediate between those with South East Asian and European ancestry living in New Zealand. Both NMOSD and particularly MS appear to be uncommon in the Indigenous populations of Australia.

Original language	English
Pages (from-to)	836-845
Number of pages	10
Journal	Journal of Neurology
Volume	269
Issue number	2
Early online date	2 Jul 2021
DOIs	https://doi.org/10.1007/s00415-021-10665-9
Publication status	Published - Feb 2022
Externally published	Yes

Keywords

Aboriginal and Torres Strait Islander
Aquaporin
Genetics
Māori
Neuromyelitis optica

Access to Document

10.1007/s00415-021-10665-9Licence: In Copyright

Cite this

Bukhari, W., Khalilidehkordi, E., Mason, D. F., Barnett, M. H., Taylor, B. V., Fabis-Pedrini, M., Kermode, A. G., Subramanian, S., Waters, P., Broadley, S. A., & The Australian and New Zealand NMO Collaboration (2022). NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand. Journal of Neurology, 269(2), 836-845. https://doi.org/10.1007/s00415-021-10665-9

@article{bc540f2cbb6a49ffa3ef5b29f53b2763,

title = "NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand",

abstract = "Background: We studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences. Methods: Cases of possible NMOSD and MS were collected from Australia and New Zealand. Clinical details, MR imaging, and serologic results were used to apply 2015 IPND diagnostic criteria for NMOSD and 2010 McDonald criteria for MS. Frequencies of self-determined ethnic ancestry were calculated for confirmed NMOSD, suspected NMOSD, and MS. Prevalence rates for NMOSD and MS according to ancestry were compared. Results: There were 75 cases with NMOSD, 89 with suspected NMSOD, and 101 with MS. NMOSD cases were more likely to have Asian, Indigenous, or Other ancestry compared to suspected NMOSD or MS. There were no differences in the clinical phenotype of NMOSD seen in Indigenous compared to European ancestry populations. Per 100,000, the prevalence estimate for NMOSD in people with Māori ancestry was 1.50 (95% CI 0.52–2.49) which was similar to those with Asian ancestry 1.57 (95% CI 1.15–1.98). NMOSD prevalence in Australian Aboriginal and Torres Strait Islander populations was 0.38 (95% CI 0.00–0.80) per 100,000. Conclusion: The prevalence of NMOSD in the Māori population is similar to South East Asian countries, reflecting their historical origins. The prevalence of MS in this group is intermediate between those with South East Asian and European ancestry living in New Zealand. Both NMOSD and particularly MS appear to be uncommon in the Indigenous populations of Australia.",

keywords = "Aboriginal and Torres Strait Islander, Aquaporin, Genetics, Māori, Neuromyelitis optica",

author = "Wajih Bukhari and Elham Khalilidehkordi and Mason, {Deborah F.} and Barnett, {Michael H.} and Taylor, {Bruce V.} and Marzena Fabis-Pedrini and Kermode, {Allan G.} and Sankar Subramanian and Patrick Waters and Broadley, {Simon A.} and {The Australian and New Zealand NMO Collaboration} and David Abernethy and Sandeep Bhuta and Stefan Blum and Mike Boggild and Karyn Boundy and Brew, {Bruce J.} and Fabienne Brilot and Brownlee, {Wallace J.} and Bundell, {Christine S.} and Helmut Butzkueven and Carroll, {William M.} and Celia Chen and Laura Clarke and Alan Coulthard and Dale, {Russell C.} and Chandi Das and Keith Dear and David Fulcher and David Gillis and Simon Hawke and Robert Heard and Henderson, {Andrew P.D.} and Saman Heshmat and Suzanne Hodgkinson and {Jimenez Sanchez}, Sofia and Kilpatrick, {Trevor J.} and John King and Chris Kneebone and Kornberg, {Andrew J.} and Jeannette Lechner-Scott and Lin, {Ming Wei} and Chistopher Lynch and Macdonell, {Richard A.L.} and Marriott, {Mark P.} and McCombe, {Pamela A.} and Cullen O{\textquoteright}Gorman and Parratt, {John D.E.} and Pender, {Michael P.} and Jennifer Pereira and Pollard, {John D.} and Prain, {Kerri M.} and Sudarshini Ramanathan and Reddell, {Stephen W.} and Cameron Shaw and Silvestrini, {Roger A.} and Mark Slee and Judith Spies and James Stankovich and Ian Sutton and Angela Vincent and Steve Vucic and Michael Walsh and Ernest Willoughby and Wong, {Richard C.} and Mark Woodhall and Yiu, {Eppie M.}",

year = "2022",

month = feb,

doi = "10.1007/s00415-021-10665-9",

language = "English",

volume = "269",

pages = "836--845",

journal = "Journal of Neurology",

issn = "0340-5354",

publisher = "Springer Medizin",

number = "2",

}

Bukhari, W, Khalilidehkordi, E, Mason, DF, Barnett, MH, Taylor, BV, Fabis-Pedrini, M, Kermode, AG, Subramanian, S, Waters, P, Broadley, SA & The Australian and New Zealand NMO Collaboration 2022, 'NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand', Journal of Neurology, vol. 269, no. 2, pp. 836-845. https://doi.org/10.1007/s00415-021-10665-9

TY - JOUR

T1 - NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand

AU - Bukhari, Wajih

AU - Khalilidehkordi, Elham

AU - Mason, Deborah F.

AU - Barnett, Michael H.

AU - Taylor, Bruce V.

AU - Fabis-Pedrini, Marzena

AU - Kermode, Allan G.

AU - Subramanian, Sankar

AU - Waters, Patrick

AU - Broadley, Simon A.

AU - The Australian and New Zealand NMO Collaboration

AU - Abernethy, David

AU - Bhuta, Sandeep

AU - Blum, Stefan

AU - Boggild, Mike

AU - Boundy, Karyn

AU - Brew, Bruce J.

AU - Brilot, Fabienne

AU - Brownlee, Wallace J.

AU - Bundell, Christine S.

AU - Butzkueven, Helmut

AU - Carroll, William M.

AU - Chen, Celia

AU - Clarke, Laura

AU - Coulthard, Alan

AU - Dale, Russell C.

AU - Das, Chandi

AU - Dear, Keith

AU - Fulcher, David

AU - Gillis, David

AU - Hawke, Simon

AU - Heard, Robert

AU - Henderson, Andrew P.D.

AU - Heshmat, Saman

AU - Hodgkinson, Suzanne

AU - Jimenez Sanchez, Sofia

AU - Kilpatrick, Trevor J.

AU - King, John

AU - Kneebone, Chris

AU - Kornberg, Andrew J.

AU - Lechner-Scott, Jeannette

AU - Lin, Ming Wei

AU - Lynch, Chistopher

AU - Macdonell, Richard A.L.

AU - Marriott, Mark P.

AU - McCombe, Pamela A.

AU - O’Gorman, Cullen

AU - Parratt, John D.E.

AU - Pender, Michael P.

AU - Pereira, Jennifer

AU - Pollard, John D.

AU - Prain, Kerri M.

AU - Ramanathan, Sudarshini

AU - Reddell, Stephen W.

AU - Shaw, Cameron

AU - Silvestrini, Roger A.

AU - Slee, Mark

AU - Spies, Judith

AU - Stankovich, James

AU - Sutton, Ian

AU - Vincent, Angela

AU - Vucic, Steve

AU - Walsh, Michael

AU - Willoughby, Ernest

AU - Wong, Richard C.

AU - Woodhall, Mark

AU - Yiu, Eppie M.

PY - 2022/2

Y1 - 2022/2

N2 - Background: We studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences. Methods: Cases of possible NMOSD and MS were collected from Australia and New Zealand. Clinical details, MR imaging, and serologic results were used to apply 2015 IPND diagnostic criteria for NMOSD and 2010 McDonald criteria for MS. Frequencies of self-determined ethnic ancestry were calculated for confirmed NMOSD, suspected NMOSD, and MS. Prevalence rates for NMOSD and MS according to ancestry were compared. Results: There were 75 cases with NMOSD, 89 with suspected NMSOD, and 101 with MS. NMOSD cases were more likely to have Asian, Indigenous, or Other ancestry compared to suspected NMOSD or MS. There were no differences in the clinical phenotype of NMOSD seen in Indigenous compared to European ancestry populations. Per 100,000, the prevalence estimate for NMOSD in people with Māori ancestry was 1.50 (95% CI 0.52–2.49) which was similar to those with Asian ancestry 1.57 (95% CI 1.15–1.98). NMOSD prevalence in Australian Aboriginal and Torres Strait Islander populations was 0.38 (95% CI 0.00–0.80) per 100,000. Conclusion: The prevalence of NMOSD in the Māori population is similar to South East Asian countries, reflecting their historical origins. The prevalence of MS in this group is intermediate between those with South East Asian and European ancestry living in New Zealand. Both NMOSD and particularly MS appear to be uncommon in the Indigenous populations of Australia.

AB - Background: We studied the prevalence of neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS) in Indigenous populations of Australia and New Zealand with the aim of assessing potential differences. Methods: Cases of possible NMOSD and MS were collected from Australia and New Zealand. Clinical details, MR imaging, and serologic results were used to apply 2015 IPND diagnostic criteria for NMOSD and 2010 McDonald criteria for MS. Frequencies of self-determined ethnic ancestry were calculated for confirmed NMOSD, suspected NMOSD, and MS. Prevalence rates for NMOSD and MS according to ancestry were compared. Results: There were 75 cases with NMOSD, 89 with suspected NMSOD, and 101 with MS. NMOSD cases were more likely to have Asian, Indigenous, or Other ancestry compared to suspected NMOSD or MS. There were no differences in the clinical phenotype of NMOSD seen in Indigenous compared to European ancestry populations. Per 100,000, the prevalence estimate for NMOSD in people with Māori ancestry was 1.50 (95% CI 0.52–2.49) which was similar to those with Asian ancestry 1.57 (95% CI 1.15–1.98). NMOSD prevalence in Australian Aboriginal and Torres Strait Islander populations was 0.38 (95% CI 0.00–0.80) per 100,000. Conclusion: The prevalence of NMOSD in the Māori population is similar to South East Asian countries, reflecting their historical origins. The prevalence of MS in this group is intermediate between those with South East Asian and European ancestry living in New Zealand. Both NMOSD and particularly MS appear to be uncommon in the Indigenous populations of Australia.

KW - Aboriginal and Torres Strait Islander

KW - Aquaporin

KW - Genetics

KW - Māori

KW - Neuromyelitis optica

UR - http://www.scopus.com/inward/record.url?scp=85109788398&partnerID=8YFLogxK

U2 - 10.1007/s00415-021-10665-9

DO - 10.1007/s00415-021-10665-9

M3 - Article

AN - SCOPUS:85109788398

SN - 0340-5354

VL - 269

SP - 836

EP - 845

JO - Journal of Neurology

JF - Journal of Neurology

IS - 2

ER -

NMOSD and MS prevalence in the Indigenous populations of Australia and New Zealand

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this